Index to Volume 6

Author Index

Aaby, P., 239
Abdulla, K., S467
Abed, Y., S467
Abramson, J. S., 689
Actor, P., S783
Albrecht, P., S540, S552, S562
Alexander, D. P., S809
Almond, J. W., S487, S516
Alsever, R. N., 625
Alving, C. R., 427, 444, 493, 532, 553, 563
Anderson, L., 472
André, F. E., S419
Aoki, F. Y., S283
Appleman, M. D., S157, S254
Arfaa, F., 364
Armstrong, R. E., S528
Arnon, S. S., S193
Assaad, F., S302
Aughey, D. R., S887
Baltimore, D., S484
Banno, Y., S11
Baptista Risi, J., Jr., S400
Baron, E. J., S249
Barriere, S. L., S809
Bartlett, J. G., S67, S235
Batley, M., 449
Batts, D., S214
Beale, A. J., S334
Bell, E. J., S385
Benenson, A. S., 1
Bennett, J. E., 619
Bennion, R. S., S132
Ben-Porath, E., S556
Berger, S. A., 802
Berndt, K. D., S678
Bernier, R. H., S371, S552
Bessman, A. N., S171
Bhattacharjee, A. K., 619
Bijkerk, H., S451
Biron, G., S545
Bjornson, A. B., 704, S34
Bjornson, H. S., 704, S21, S30
Blanchard, R. J., S283
Blaser, M. J., 345, 625
Blondel, B., S535
Boisvert, W. E., S678
Boldreghini, S. J., S896
Boone, E. J., S552
Boscia, J. A., S844
Böttiger, M., S548
Bottone, E. J., 423
Boucher, M., S157
Boyer, B. L., S901
Brade, H., 428, 432, 546
Branham, S. E., 579
Brannan, W., S844
Brenner, E. R., 135
Brook, I., 601, S187
Bruckner, D. A., S59, S249
Bryan, C. S., 135
Buchanan, C. N., S705
Buchwald, D. S., 345
Bukh, J., 239
Bump, C. M., 771
Burns, W. H., 156
Busch, D. F., S115
Canawati, H. N., S171
Cann, A. J., S487
Cantrell, J. L., 439, 567
Caplan, D. B., S705
Carlsson, B., S356
Carr, C., Jr., 497
Cato, E. P., S3
Chaki, H., 478
Chambers, H. F., S870
Chernesky, M. A., S525
Chin, J., S581
Chin, T. D. Y., S369
Chun, J. H., S345
Citron, D. M., S51, S101, S177
Clemens, J. D., 589
Coffi, E., S433
Cohen, H., S350
Conte, J. E., Jr., S777, S809
Contreras, G., S528
Corrodi, P., S80
Cortez, L. M., S844
Costerton, J. W., S608
Counts, G. W., 640
Coutinho, A., 524
Cox, C. E., S839
Crainic, R., S535
Creese, A. L., S404, S589
Cruz, R. R., S408
Cucheral, G. J., Jr., S260
Cudmore, M., S214
Cummins, P., S552
Cutler, R. E., S803
Dalakas, M. C., S562
Dall, L., S853
Dan, M., 147
DeBenedictis, K. J., S901
de Repentigny, L., 301
Díaz, S., 775
Dinarello, C. A., 51
Docampo, R., 223
Dömök, I., S413
Dong, D.-X., S431
Dowell, V. R., Jr., S202
Drake, T. A., S870
Drusano, G. L., 13, 357
Dudek, E. J., S678
Dudley, M. N., S821
Duncan, W. C., S875
Dunn D. L., S139
Durack, D. T., 791
Ebright, J., S214
Edberg, S. C., 802
Eddins, D. L., S424
Ehrie, M. G., S657
Eisenberg, J. M., S905, S909
Elder, H. A., S734
Elisberg, B. L., S519
Ell, S. R., 866
El Massri, M., S467
El Tibbi, A. G., S467
Emini, E. A., S505
Epstein, J. B., 96
Evans, A. S., S463, S571
Evans, D. M. A., S516
Fabian, T. C., S896
Fanget, B., S341
Farmer, J. J., III, 633
Feder, H. M., Jr., 181
Fekety, R., S214
Felice, G. A., 640
Ferguson, M., S510, S516
Fernández de Castro, J., S397
Ferris, F. Z., 715
Finberg, R. W., S91
Finegold, S. M., S1, S45, S96, S101, S123, S177, S184, S229
Finkler, S. A., S909
Ford, L. C., S96
Forni, L., 524
Forsgren, S., 524
Foster, S. O., S433
Fox, J. P., S352
Frank, J. A., Jr., S552
Freeman, J., 285
Freimer, E. H., 832
Freudenberg, M. A., 483, 546
Fujii, R., S751
Furesz, J., S528
Gadless, B. R., S552
Galanos, C., 428, 483, 546
Gallis, H. A., 164
Gambertoglio, J. G., S809
Garibaldi, R. A., 181
Gates, J., 214
Gear, J. H. S., S379
Geckler, R. W., S847
Gemski, P., 444
George, W. L., S101, S208
Gerichter, C. B., S467
Gessard, C., S775
Gibson, T. P., S689

Glaudemans, C. P. J., 619
Goldblum, N., S313, S556
Goldstein, E. J. C., S177
González, P. A., 775
Goodman, J. S., S847
Goodman, S. A., 511
Gorbach, S. L., S85
Gordon, S. C., 338
Gough, P., S821
Grachev, V. P., S321
Granfors, K., 421
Granneman, G. R., S689
Grant, J. A., S345
Greenwood, B. M., 374
Gregg, M. B., S577
Gregory, D. F., 640
Grenier, B., S545
Griffiss, J. M., 640
Grist, N. R., S385
Gudmundsson, S., S711
Guice, S. L., S844
Gyorkey, F., 745
Gyorkey, P., 745
Haase, D. A., S283
Halstead, S. B., 251
Hammill, H. A., S96
Hamza, B., S545
Handscher, R., S467
Hanson, L. Å., S356
Hara, K., S128
Harding, G. K. M., S283
Hatch, M., S424
Hauptmann, R., S487
Heimbach, D. M., S744
Heimdahl, A., S270
Henderson, R. H., S475
Heseltine, P. N. R., S254
Hewitt, W. L., 13
Heymann, D. L., S376
Hickey, W. F., S657
Hickingbotham, M., S821
Hightower, A., 625
Hirsch, M. S., 726
Hirschman, S. Z., S698
Ho, D. D., 726
Hofstad, T., 189
Holdeman, L. V., S3
Holmberg, S. D., 633
Holmes, K. K., 640
Holst, O., 542
Horaud, F., S535
Horstmann, D. M., S301
Hovelius, B., 328
Hsiung, G. D., 33
Hughes, J., S552
Hunter, J. R., 732
Iannini, P. B., S865
Imoto, M., 478
Imura, N., S494
Inage, M., 478
Inamatsu, T., S147
Izutzu, K. T., 96
Jacob, L.S., S791, S816, S839
Jacobs, D. M., 501
Jackson, L., 156
Jalil, F., S356
Jameson, B. A., S505
Jay, F., 546
John, T. J., S438
Johnson, J. D., 715
Johnson, R. H., S552
Johnson, R. T., S568
Jordan, W. S., Jr., S594
Jousimies-Somer, H. R., S45
Juranek, D. D., 313
Kager, L., S270
Kallal, J. E., S689
Kanaaneh, H., S556
Kaplan, J., S424
Kaplan, J. C., 726
Karakusis, P. H., S728
Kasper, D. L., S25, S91
Kataoka, Y., S494
Katz, D., 783
Kaye, D., S835, S844
Kern, M., 506
Kesseng-Maben, G., S433
Kew, O. M., S499
Khan, S. R., S356
Kim-Farley, R., S424
Kinnear, J., S552
Kinsky, S. C., 558
Kirkpatrick, J. R., S283
Kirmani, N., 156
Kleine, B., 483, 524
Klempner, M. S., S40
Kobayashi, T., S11
Koffer, H., S909
Kohara, M., S494
Kono, H., S11
Koskiniemi, M., 608
Kraft, M., S552
Krause, R. M., 270
Krezlewicz, A., S562
Krieger, R. E., S844
Kuller, L. H., 200
Kunin, C. M., 129
Kunkel, M. J., S865
Kusumoto, S., 428, 478
Lammers, J. L., S887
La Montagne, J. R., 133
Landry, M. L., 33
Lange, S., 880
Lapinleimu, K., S457
Larsson, P., 880
Lasch, E. E., S467
Lauter, C. B., 338
Layne, P., S791
Lee, B. A., 640
Leedom, J. M., S254
Leitner, L., S556
León de Coto, E. M., S442
Lerner, S. A., S678
Letvenuk, L., S345
Levison, M. E., S844
Lewis, R. P., S165
Lindberg, A. A., S25
Lindblad, B. S., S356
Lipsky, B. A., 214
Lisse, I. M., 239
Ljungaqs-Esteves, K., S302
Lönngren, J., S25
Lou, M. A., S816
Lucia, H. L., 33
Lüderitz, O., 428
Lukens, J., S214
Lundbeck, H., S483
McBean, A. M., S552
McBride, M. E., S875
McCormack, G. D., S847
McCormick, M. L., 715
McCutchan, J. A., 669
MacDonald, B., S552
McGowan, J. E., Jr., 285
McKenzie, G. R., 428
Mackowiak, P. A., 649
McNamee, W., S844
McNicholas, P. A., 449
Madden, D. L., S562
Mader, J. T., S857
Madonna, G. S., 535
Magrath, D. I., S510
Mahler, H., 265
Maire, B., S463
Maki, D. G., S711, S887
Malamy, M. H., S260
Malmborg, A. S., S270
Mangiante, E. C., S896
Manischewitz, J., 156
Marcus, O., S467
Mårdh, P.-A., 328
Marsden, P. D., 736, 855
Martin, J. F., S480
Martin, W. J., S59
Martinez-A., C., 524
Marzouk, J., S853
Mathison, G. E., S101
Mattsby-Baltzer, I., 444, 553
Mayer, H., 542
Mayo, D. R., 33
Melnick, J. L., 745, S323, S387, S467
Mendelson, M. H., S698
Mergenhagen, S. E., 519
Metchnikoff, E., 761
Meyer, R. D., S101
Meyers, B. R., S698
Mills, J., S853, S870
Minor, P. D., S487, S510, S516
Mogabgab, W. J., S721
Montagnon, B. J., S341
Montgomerie, J. Z., S171
Monto, A. S., 720
Moody, M. R., 357

Moore, M., S424, S552
Moore, W. E. C., S3
Moreno, S. N. J., 223
Morgan, S. I., S844
Morrison, A. J., Jr., S627
Morrison, D. C., 427, 497, 511, 528
Mulligan, M. E., S222, S229
Munkenbeck, P., 511
Murray, P. M., S123, S184
Nagar, D., 715
Nagel, J., S350
Nakamura, R., S157
Nakata, M. M., S165
Narang, P. K., 732
Nashed, M. A., 472
Nathanson, N., S308
Nauseef, W. M., 131
Navin, T. R., 313
Nerhood, L., S552
Nerkar, D., 546
Neu, H. C., S667
Neumeyer, B. A., 455
Newman, M. G., S107
Nichols, L., S711
Nichols, R. L., S276
Nicolle, L. E., S283
Nightingale, C. H., S821
Nikaido, H., 488
Nishimura, T., S751
N'jie, H., S433
Nomoto, A., S494
Nord, C. E., S270
Norden, C. W., 200
Noro, T., S147
Nottay, B. K., S499
Nozawa, Y., S11
Ofosu-Amaah, S., S318
Ogra, P. L., S361
Ogston, A., 122
Oker-Blom, N., S461
Omata, T., S494
Onderdonk, A. B., S25, S91
Osterhaus, A. D. M. E., S335
Owens, W. E., S96
Pacific Northwest Meningococcal Study Group, 640
Packer, N. H., 449
Pang, Q.-F., S432
Papadopoulos, N. M., S562
Parent, G., S463
Parisier, S. C., S698
Peacock, J. E., Jr., 689
Pearson, E. W., S345
Pennington, J. E., S657, S769
Penttinen, K., S461
Perfect, J. R., 791
Perkins, F. T., S523
Petersen, I., S471
Peterson, J., 567
Pierce, N. F., 563
Pitkin, D. H., S816
Platt, R., S759, S769, S829, S880
Plorde, J. J., 214
Pluznik, D. H., 519
Pobor, G., 524
Polk, B. F., S67
Pollack, M., S617, S769
Pontzer, R. E., S844
Poser, C. M., 132
Pottage, J. C., Jr., S728
Quinnan, G. V., Jr., 156
Quintiliani, R., S821
Qureshi, N., 439, 567
Racaniello, V. R., S514
Raetz, C. R. H., 463
Raff, M. J., 715
Redmond, J. W., 449
Reeve, P., S487
Reinarz, J. A., S857
Reingold, A. L., 625
Reiss, E., 301
Reynolds, K. L., 135
Ribi, E., 439, 567
Ribi, H. O., 567
Richardson, E. C., 493, 532, 563
Rick, P. D., 455, 535
Rietschel, E. Th., 428, 432
Robbins, F. C., S596
Robinson, D., S586
Rohde, J. E., 840
Rolfe, R. D., S73
Rook, A. H., 156
Rose, D., S821
Rosenblatt, J. E., S242
Rosner, B., S829
Roumiantzeff, M., S545
Rowan, N. M., S901
Roy, I., S734
Russa, R., 432
Ryan, P. A., 357
Sabath, L. D., S643, S769
Sabbaj, J., S152
Sabin, A. B., S391
Sacci, J. B., Jr., 563
Saito, A., S128
Salimath, P. V., 542
Salk, J., S444, S463, S540
Sande, M. A., S870
Santos, G. W., 156
Sapico, F. L., S171
Saral, R., 156
Schild, G. C., S487, S510, S516
Schimpff, S. C., 13, 357
Schlumberger, M., S463
Schonberger, L. B., S424
Schooley, R. T., 726
Schuddekopf Jordan, N., S821
Scully, B. E., S667
Seefried, A. V., S345
Senitzer, D., 832
Sennello, L. T., S689
Serota, A. I., S132
Sever, J. L., S562
Shapiro, E. D., 589
Shapiro, E. R., S698
Shapiro, M. E., S91
Sheehan, D. J., 423
Shekarchi, I. C., S562
Shiba, T., 428, 478
Shimada, K., S147
Shimamoto, T., 478
Shimojo, H., S427
Silva, J., S214
Simmons, R. L., S139
Sinkovics, J. G., 745
Slutkin, G., S853
Smego, R. A., Jr., 164, 791
Smith, H., 390
Smith, P. W., 129
Smith, T., 280
Smits, A. J., 239
Sosa, A. C., 775
Spearman, J. G., 640
Spence, L., S331
Spitz, M., S510
Stagg, R. J., S809
Standiford, H. C., 357
Stanway, G., S487
Stiver, H. G., S283
Stoeckel, P., S463
Strittmatter, W., 546
Stuart-Harris, Sir C., 405
Suganuma, T., S494
Sutter, V. L., S62
Swartz, T. A., S313, S556
Syrjamaki, C., S214
Takayama, K., 439, 567
Takeuchi, Y., 488
Tally, F. P., S260
Tanamoto, K., 428
Tanner, D. J., S924
Tashjian, L. S., 689
Taskinen, E., 608
Taylor, M. L., 775
Tenover, F. C., 214
Thoms, M. L., S552
Toivanen, A., 421
Toriello, C., 775
Toscani, M., S821
Toyoda, H., S494
Trenholme, G. M., S728
Truelove, E. L., 96
Tsao, M. M. P., 783
Ueno, K., S11
Umezawa, H., 412
Urayama, K., S147
Usui, T., S128
Vaheri, A., 608
Vallancourt, R. J., S328
van den Broek, P. J., 107
van der Marel, P., S335
van der Meer, J. W. M., 107
van Steenis, G., S335, S463, S540

van Wezel, A. L., S335, S356, S463, S540
Velena, K., 546
Verret, C. R., 452
Viarme, F., S545
Vincent-Falquet, J. C., S341
Vogel, S. N., 535
von Magnus, H., S471
Vukajlovich, S. W., 511, 528
Wachmann, B., S528
Wahl, L. M., 535
Wallace, R., S157
Ward, N. A., S591
Watanabe, K., S11
Watts, C., S552
Weckesser, J., 542
Weckström, P., S461
Weinberg, E. D., 814
Weintraub, A., S25
Wenzel, R. P., S627, S769
Werk, C., S214
Wexler, H., S229
Wilhelm, P. A., S59
Williams, R. A., S132
Willis, A. T., S293
Wilson, S. E., S132
Wimmer, E., S505
Witte, J. L., S171
Wolinsky, E., 421
Wollenwebber, H.-W., 432
Wu, Y. H., S816
Xueref, C., S545
Yamaguchi, K., S128
Yonekura, M. L., S157
Young, D. A., 455
Young, L. S., S603, S769
Zähringer, U., 428, 432
Zaleznik, D. F., S91

Subject Index

Abscesses, due to *S. aureus*, 122 (classic paper)
Acid-fast bacilli, microscopy for, factors affecting clinical value of AFB smear, 214, 771 (letter)
Acute-phase response, mediated by interleukin-1, 51
Acylampicillins, microbiology and pharamcology of, clinical trials with, 13
Adenoviruses, immunization against in the military, 9
Aedes aegypti
  control strategies for, past and present, 257
  as vector of dengue viruses, 251
Aeromonas hydrophila, enteritis due to, 633
Africa
  control of poliomyelitis in, S318, S433
  use of IPV in, S463
Agar dilution, for testing susceptibilities of anaerobic bacteria, S254
AIDS
  comparative immunology of, 745
  definition of (CDC), 273
  epidemiology of, study design for, 720
  infectious agent as cause of, Koch's postulates to detect, comparison to tuberculosis, 270
  opportunitistic infections with, 273
  possible viral interactions in, 726
Aminoglycosides
  in comparative trials for intraabdominal and female genital tract infections, S283
  against *P. aeruginosa*, S678
Amphotericin B, for treatment of candida meningitis, 791
Anaerobic bacteria (*see also names of specific bacteria*)
  antibiotic-induced pseudomembranous colitis and diarrhea
    clinical aspects of, S208
    epidemiology of, due to *C. difficile*, S222
    etiologic agents of, S214
    PAGE, with *C. difficile*, S229
    treatment of, S235
  antimicrobial agents for
    effects
      future research, directions for, S293
      on normal gastrointestinal flora, S270
    prophylaxis for intraabdominal surgery, S276
    susceptibilility testing, S242, S249, S254
    therapy, for intraabdominal and female genital tract infections, S283
  clinical bacteriology of, S45–S61
  host defenses against
    complement, S34
    PMNs, S40
  infection due to
    animal models of, S91–S100
    in biliary tract, S147
    in bite wounds, S177
    in bones and joints, S165
    in botulism and tetanus, S202
    in brain abscess and cerebritis, S101
    in burn wounds, S184
    in children, S187, S193
    in diabetic foot, S171
    endometritis, postcesarean, S157
    head, neck, ear, nose, and throat, S115
    intraabdominal, S91, S139
    liver abscess, S152
    mediastinitis, S123
    mesenteric ischemia, S132
    oral and dental, S107
    pulmonary, S128
    in unilateral utero-tubo-ovarian abscess, S96
  in normal flora
    intestinal, S73
    oral, S62
    vaginal, cervical, S67
  in pathogenic processes other than infection
    breast cancer and association with intestinal flora, S85
    after jejunoileal bypass, S80
  role in disease of, symposium on, S1–S299
  taxonomy of new species, S3
  virulence factors of
    activation of Hageman factor by *Bacteroides*, S30
    capsular polysaccharides and lipopolysaccharides of *B. fragilis*, S25
    enzymes associated with, S21
    toxins of *C. difficile*, S11
Animal model of infections
  for genital herpesvirus infection, 33
  for intraabdominal sepsis, S91
  for utero-tubo-ovarian abscess, S96
Anthrax bacilli, relationship to phagocytes, 761 (classic paper)
Antibiotic-associated infection, pseudomembranous colitis, S208, S229, S235
Antibiotics (*see also names of individual agents*)
  costs of, S905, S909, S924
  impact of on normal gastrointestinal flora, S270
  parenteral, cost of administration of, S924
  prophylaxis with
    for biliary tract surgery or hysterectomy, S887
    with cefonicid or cefazolin for prosthetic joint surgery, S901
    comparison of cefonicid and cefoxitin for colorectal and small bowel surgery, S896
    in surgery, S880
  susceptibility of *P. aeruginosa* to, S643
  susceptibility testing of, S242, S829
Antibodies
  to lipid A, in humans, 553
  monoclonal
    to *Pseudomonas* antigens, S769
    for study of poliovirus, S510, S535
Aquatic bacteria (*see Pseudomonas aeruginosa*)
Acquired immune deficiency syndrome (*see* AIDS)
Arthritis, mumps (*see* Mumps arthritis)
Arthritis, rheumatoid (*see* Rheumatoid arthritis)
Arthritis, septic (*see* Septic arthritis)
Ascariasis, epidemiology and control of, 364
Ascaris lumbricoides, 364
Aspergillosis, immunodiagnosis of, antigen detection in, 301
Azlocillin, microbiology and pharmacology of, clinical trials with, 13
Bacterial antagonism, in intestinal flora, S75

Bacterial meningitis (*see* Meningitis, acute bacterial)
Bacteroides fragilis
abscesses due to, S25
animal models for infection
intraabdominal sepsis, S91
utero-tubo-ovarian abscess, S96
capsular polysaccharides of, S25
host defense against, S40
lipopolysaccharides of, S25
pathogenic mechanisms of, 189
resistance of
mechanisms, S260
susceptibility to β-lactam agents, S254
Bacteroides species
in burn-wound infections, S184
Hageman factor, activation of, S30
host resistance to, role of complement in, S34
infections in children, S187
infections, treatment of, S260
nomenclature for, new species, S3
pathogenic mechanisms of, bacterial adherence, encapsulation, 189
penicillin failure in tonsillitis, as cause of, 601
Belgium, control of poliomyelitis in, S419
Bestatin, immunomodifier, 413
β-Lactam antibiotics
against *P. aeruginosa*, S678
effect of hydrogen ion and protein concentration on in vitro susceptibility to, S829
epidemiology and susceptibility of *B. fragilis* to, S254
microbiologic and pharmacologic properties, integration of, 357
new, comparison of, 357 (hypothesis)
β-Lactamase
of *P. aeruginosa*, S643
-producing organisms, in tonsillitis, 601
Biliary tract infection, due to anaerobic bacteria, S147
Biliary tract surgery, antibiotic prophylaxis for, S887
Biofilms, of *P. aeruginosa*, S608
Bite-wound infection, role of anaerobic bacteria in, S177
B lymphocytes
lipid A binding, 506, 519
proliferation of, response to lipid A, 528
stimulation by lipid A subunits, 511
Body fluids and tissue, penetration of cefonicid into, S816
Bone and joint infections, due to anaerobic bacteria, S165
Bone marrow transplantation, CMV in, 156
Botulism
food-borne, infant, wound, clinical and microbiologic aspects of, S202
infant, due to *C. botulinium*, S193
Brain abscess (*see* Anaerobic bacteria, infection due to)
Brazil
leishmaniasis in, 736
poliomyelitis in, control of, S400, S404
Breast milk, penetration of cefonicid into, S816
Burkitt's lymphoma, and AIDS, 745
Burn injury (*see* Thermal injury)
Canada, use of OPV in, S331
Cancer
breast, association with intestinal flora, S85
treatment with low-molecular-weight immunomodifiers produced by microorganisms, 412
Candida albicans, oral infection due to, pathogenesis, host defense, 96
Candida species
hepatic involvement with, 689
meningitis due to, therapy for, 791
Candidiasis
antigen detection in, 301
chronic mucocutaneous due to phagocyte dysfunction, 107
in immunocompromised hosts, 689
immunodiagnosis of, current trends in, 301
oral, host defense in, pathogenesis of, 96
Capnocytophaga species, as new genus for *B. ochraceus*, S6
Capsular polysaccharides
of *B. fragilis*, chemical analysis of, abscess formation due to, S25
of *C. neoformans*, structural features of, 619
Caribbean (*see also* Cuba), use of OPV in, S331
Catheter-induced endocarditis, 783
Catheters, urinary infection with *P. aeruginosa*, S734
Cefamandole
comparison with cefonicid for treatment of lower respiratory tract infections, S847
comparison with cefonicid for treatment of urinary tract infections, S839
Cefazolin
comparison with cefonicid for treatment of soft tissue infections, S853
for prophylaxis in prosthetic joint surgery, S901
Cefonicid
clinical and economic impact of, symposium on, S777–S937
economic considerations of, S905, S909, S924
efficacy of
in endocarditis, S857, S870
in gonorrhea, S875
in osteomyelitis, S865
overviews on, S835, S857
in respiratory tract infections, S847
in soft tissue infections, S853
in surgical prophylaxis
antibiotic prophylaxis in surgery, S880
for biliary tract operations and hysterectomy, S887
for colorectal and small bowel surgery, S896
for hip or knee replacement, S901
in urinary tract infections, S839, S844
pharmacokinetics of
overview of, S803
penetration into body fluids, S816
in renal failure, S809
susceptibility testing based on, S829
tissue penetration and half-life, S821
Cefoperazone, comparison with cefotaxime and moxalactam, 357
Cefotaxime, hypothesis for comparision with cefoperazone and moxalactam, 357
Cefoxitin
in comparative trials for intraabdominal and female genital tract infections, S283
comparison with cefonicid for biliary tract surgery and hysterectomy, S887

Cefsulodin, for infection due to *P. aeruginosa*
with aminoglycosides, S678
in burns, S744
in children, S751
comparison with other agents, S667
in external otitis, S698
in lower respiratory tract infection, S711
in osteomyelitis, S728
predictors of response for, S759
in renal impairment, S689
in skin and soft tissue infection, S721
symposium on, S603–S774
in urinary tract infection, S734
Ceftazidime, renal dysfunction in elimination of, determinants of elimination, 732
Ceftizoxime, comparative trials for intraabdominal and female genital tract infections, S283
Cell-mediated immunity, depression of, associated with pregnancy, 814
Cephalosporins, modification of dosage in renal failure, S803
Cerebrospinal fluid, alterations in HSV encephalitis, 608
Cerebritis (*see* Anaerobic bacteria, infection due to)
Chagas' disease
epidemiology and control of, 855
phagocyte-derived oxygen metabolites in, 214
Chediak-Higashi syndrome, and phagocyte dysfunction, management of, 113
China, People's Republic of, OPV immunization in, S431, S432
Cholera
in famous people, 805–807
immunization against in the military, 6
Chronic diseases, identifying infectious etiologies of, 200
Clindamycin
in comparative trials for intraabdominal and female genital tract infections, S283
and resistant *Bacteroides*, S260
Clostridium botulinium
in sudden infant death syndrome, S193
toxin types, incidence in food-borne, infant, and wound botulism, S202
Clostridum difficile
colitis and diarrhea due to, S214
intestinal disease due to, epidemiology of, S222
nosocomial infection due to, S222
pseudomembranous colitis due to, S208
PAGE for, S229
treatment of, S235
in sudden infant death syndrome, S193
toxin, bacterial, from, S11
Clostridium perfringens, pleural empyema due to, 715
Clostridium species (*see also names of specific species*)
nomenclature, new species, S3
in infections in children, S187, S193, S202
in thermal injury, S184
Colitis
antibiotic-associated, drug-induced, in hamsters, S214
due to *C. difficile*, S214, S208, S229, S235
Colorectal surgery, comparison of cefonicid and cefoxitin for prophylaxis in, S896
Complement, in opsonization and phagocytosis of bacteria by PMNs, S34
Corynebacterium equi, nomenclature for, 421 (letter)
Cost-benefit analysis, in assessment of pharmaceutical innovations, S905
Costa Rica, poliomyelitis vaccination in, S442
Cost containment
for antibiotics, S924
in therapy for osteomyelitis using once-daily cefonicid, S865
Cost-effectiveness analysis, in assessment of pharmaceutical innovations, S905
Cryptococcus neoformans, capsular polysaccharides of, 619
Cryptosporidiosis
clinical manifestations in humans and animals, 316
in patients with AIDS, 313
treatment for, 322
Cryptosporidium species, gastroenteritis in humans due to, 313
Cuba, vaccination against poliomyelitis in, S408
Cystic fibrosis, and *P. aeruginosa* infections, S705
Cystitis, systemic, as a symptom of urinary tract infections due to *S. saprophyticus*, 328
Cytomegalovirus, and cytotoxic T cells, cellular immunity to, in bone marrow transplantation, 156
Dengue
hemorrhagic fever and shock syndrome, 253
immunization against in the military, 10
primary health care, control of, 260
vaccine against, 260
vectors, epidemiology of, 251
Denmark, poliomyelitis vaccination in, S471
DHS/DSS (*see* Dengue)
Diabetes mellitus, juvenile, identifying infectious etiologies of, 200
Diabetic foot, infected, S171
Diarrhea
acute, epidemiology, pathophysiology, and treatment of, 840
due to antimicrobial therapy and *C. difficile*, S208
fatal, in famous people, 805–807
Dictyostelium discoideum, fatty acyl amidases of, in degradation of lipopolysaccharide, 452
Diphtheria
in famous people, 805–807
immunization against in military, 8
Ear, nose, and throat, infections of, due to anaerobic bacteria, S115
Empyema
due to *C. perfringens*, 715
in famous people, 810
Encephalitis, herpes simplex virus, CSF alterations in, 608
Endocarditis
due to *S. aureus*, failure of once-daily cefonicid, S870
due to *S. aureus*, treatment with cefonicid, S857
induced by venous catheter, 783
Endogenous pyrogen, leukocyte endogenous mediator as interleukin-1, 51
Endometritis, postcesarean, predictive value of amniotic membrane cultures, S157
Endotoxin (*see also* Lipid A)
classic paper on, 579
distribution and excretion in rats, 483
lipid A component of, 432
Enteritis, due to *A. hydrophila* and *P. shigelloides*, 633

Enteroviruses, nonpolio, S379–S390
Enzymes
  antibiotic-modifying, of *P. aeruginosa*, S643
  produced by anaerobic gram-negative bacteria, S21
Eradication of infectious diseases, prospects for, 405
Estrogen, metabolism of by intestinal flora, S85
Ethics, academic and industrial, 129–132 (letters)
Factor XII (*see* Hageman factor)
Finland
  control of poliomyelitis in, S457
  use of IPV in, S461
5-Fluorocytosine, for treatment of candida meningitis, 791
Forphenicinol, as immunomodifier, 415
Free radicals, from drugs and phagocytic cells, action on *T. cruzi*, 214
Fusobacterium nucleatum, pathogenic mechanisms of, 189
Fusobacterium species, in infections in children, S187
Gastrointestinal flora, normal, as altered by antibiotics, S270
Gastrointestinal surgery, antibiotic prophylaxis in, S270
Gaza, control of poliomyelitis in, S467
Genital infection
  due to herpesvirus, pathogenesis and chemotherapy in guinea pig model, 33
  in women, comparative trials for therapy of, S283
Gonorrhea
  comparison of treatment with cefonicid and penicillin, S875
  epidemiology of, 669
  in famous people, 805–807
  treatment with cefonicid, S857
Granulomatous disease, chronic, and phagocyte dysfunction, management of, 111
Hageman factor (Factor XII), activation of by lipopolysaccharide of *Bacteroides* species, S30
Head and neck, infections of, due to anaerobic bacteria, S115
Hematologic alterations, after thermal injury, 704
Hemodialysis, pharmacokinetics of cefonicid in patients undergoing, S809
Hepatic abscess, due to *Candida* species, 689
Hepatitis, in famous people, 805–807
Herpes simplex virus
  encephalitis due to, 608
  genital infections with, in guinea pig model, 33
Histoplasmosis, pathogenesis and immune regulation of, 775
Hospital costs, antibiotic cost containment, S924
Hospital epidemiology, effects of time and severity of infection on cost of nosocomial infection, 285
Host-defense mechanisms, effect of interleukin-1 on, 51
Host resistance, following thermal injury, 704
Human T cell leukemia virus, in AIDS, 745
Hungary, use of OPV in, S413
Hyper-IgE syndrome, and phagocyte dysfunction, management of, 114
Hypogammaglobulinemia, and phagocyte dysfunction, management of, 115
Hysterectomy, antibiotic prophylaxis for, S887
IL-1 (*see* Interleukin-1)
Immunity, cell-mediated, depression of, associated with pregnancy, 814
Immunization (*see also names of specific diseases*), military contribution to, 1
Immunoassays, enzyme, for immunodiagnosis of candidiasis and aspergillosis, 301
Immunologic alterations, after thermal injury, 704
Immunomodifiers, low-molecular-weight, produced by microorganisms, 412
Immunotherapy, for cancer, with lipid A, 567
India, control of poliomyelitis in, S438
Infectious diseases (*see also* Primary health care *and names of specific infections*)
  in famous people, 802
  prospects for eradication of, 405
Influenza
  immunization against in the military, 9
  vaccines, determination of neurologic reactions to, 132 (letter), 133 (reply)
Interleukin-1
  activity of, 65–81
  cell sources and inducers of, 57
  chemical nature of, 63
  mechanisms of actions of, 82
International Congress for Infectious Diseases, papers from
  on AIDS, 271, 745
  on eradication of infectious disease, 405
  on low-molecular-weight immunomodifiers, 412
  on primary health care, 265
Intestinal flora
  alterations in, caused by antibiotics, S270
  changes of, in mesenteric ischemia, S132
  effect on estrogens, S85
Intraabdominal infection
  animal model for, S91
  comparative trials in therapy of, S283
  liver abscess due to anaerobic bacteria, S152
  role of anaerobic bacteria in, S139
Intraabdominal sepsis, animal model for, S91
Intraabdominal surgery, antibiotic prophylaxis for, S270
Ischemia, mesenteric, changes in colonic flora, S132
Israel (*see also* Gaza), control of poliomyelitis in, S313
Japan, control of poliomyelitis in, S427
Jejunoileal bypass, change in flora of the small intestine following, S80
Kaposi's sarcoma, and AIDS, 745
Keats, John, 390 (historical article)
Koch's postulates, to detect infectious cause of AIDS, 270
Krumbhaar, Edward, letter to, from Theobald Smith, 280 (classic paper)
Latent infections, and malignant neoplasms, 649
Leishmaniasis, epidemiology and control of, 736
Lipid A
  immunology of
    antibodies in humans, 553
    enhancement of mucosal immunogenicity of cholera toxin, 563
    immunotherapy with lipid A, 567
    immunogenic properties, 546, 558
    liposomal immunogenicity, 558
  interaction of, with lymphocytes and macrophages
    binding vs. triggering sites, 519
    defective, in mice, 519
    induction and clonal expansion, 524

mitogenic response, 532
proliferation, dependency on lipid A, 528
stimulation by *S. typhimurium* lipid A precursor, 535
interaction of, with membranes
binding
to murine lymphocytes, 501
to responder and nonresponder B lymphocytes, 506
of erythrocytes, 497
between lymphocytes and lipid A subunits, 511
mitogenic activity of fractions, 493
with spin-labeled phospholipids, domain formation, 488
structural aspects of, 428, 432
chemical and NMR analysis of, 449
heterogeneity of, 444
separation and characterization of, relationship to toxicity, 439
symposium on, 427–578
synthesis of
altered, effect on synthesis of protein of *S. typhimurium* outer membrane, 455
chemical alteration and excretion in rats, 483
convergent, 472
enzymatic, 463
monosaccharide precursors, molecular structure and biologic function of, 463
recent developments in synthesis of analogues and proposed structure, 478
Lipid X, from *E. coli*, mitogenic properties of, precursor of lipid A, 463
Lipopolysaccharides (*see also* Lipid A)
of *B. fragilis*, S25, S30
binding of, to lymphocytes, 497
chemical alteration and excretion of, 483
enzymatic degradation of, 452
interaction of, with erythrocyte membranes, 497
of nonresponder mice, dependency on lipid A of lymphocyte proliferation, 528
structural principles and biologic activities of, 428, 432
Liposomes, lipid A in, 493, 558, 563
Liver abscess, due to anaerobic bacteria, in mice, S152
Lower respiratory tract infections, comparison of cefonicid and cefamandole for treatment of, S847
Lupus (*see* Systemic lupus erythematosus)
Malaria
in famous people, 805–807
immunization against in the military, 10
Measles, age of infection as risk factor for subacute sclerosing panencephalitis, 239
Mediastinitis, due to anaerobic bacteria, secondary to esophageal perforation or odontogenic cause, S123
Meningitis, acute bacterial
due to *Candida* species, therapy for, 791
epidemiology of, 374
due to *H. influenzae* type b, control of in developing countries, 379
meningococcal
control of in developing countries, 379
immunization against in the military, 10
pneumococcal, control of in developing countries, 379
Meningococcal disease
epidemiology of, 625
due to group A *Neisseria* in Pacific Northwest, 640
Metronidazole, in comparative trials for intraabdominal and female genital tract infections, S283
Mexico, vaccination against poliomyelitis in, S397
Mezlocillin, microbiology and pharmacology of, clinical trials with, 13
Microbial latency, 649
Microbroth method, susceptibilities of anaerobic bacteria, compared with agar dilution, S254
Military medicine, contributions to immunization, 1
Monoclonal antibodies (*see* Antibodies, monoclonal)
Moxalactam, comparison with cefoperazone and cefotaxime, 357
Mumps arthritis, review of literature, incidence, complications, pathogenesis, 338
Mycobacterium tuberculosis, microscopy for, 214, 771 (letter)
Myeloperoxidase, deficiency of and phagocyte dysfunction, management of, 113
Neisseriae, nongonococcal, nonmeningococcal, significance in blood culture, as pathogens in meningitis, endocarditis, septicemia, treatment of infections due to, 181
Neisseria gonorrhoeae infections, single-dose therapy for, S857
Neisseria meningitidis
group A, in Pacific Northwest, 640
pericarditis due to, 625
Neonates, septic arthritis in, 147
Netherlands, The, control of poliomyelitis in, S451
Nitrobacter species, lipid A of, 542
Nocardia brasiliensis, clinical spectrum and infections due to in U.S., 164
Nongonococcal urethritis, epidemiology of, 669
Nosocomial infection
due to *C. difficile*, S222
estimates of cost of, effects of time and severity on, epidemiologic methods for study of, 285
due to *P. aeruginosa*, S627
Oncogene activation, in AIDS, 745
Orofacial and odontogenic infections, anaerobic, S107, S123
Osteomyelitis
bacterial, treatment with cefonicid for, S857
due to malignant external otitis, S698
due to *P. aeruginosa*, S728
treatment with once-daily cefonicid for, S865
Otitis, invasive external, treatment with cefsulodin, S698
PAGE (*see* Polyacrylamide gel electrophoresis)
Penicillins
acylampicillins, new, microbiology and pharmacology of, clinical trials with, 13
failure of, to eradicate streptococci from tonsils, 601
Pericarditis, due to *N. meningitidis*, 625
Periodontal disease, bacterial invasion in, S107
Phagocytes
and anthrax bacilli, 761 (classic paper)
free radicals–mediated action on *T. cruzi*, 214
functional disorders of, diagnosis, prevention, treatment, management of, 107
Pharmacokinetics
application to antibiotic dosing, principles, and drug therapy, S803

comparison of cefonicid, cefazolin, and cefoxitin, S821
deposition of cefonicid in renal failure, S809
Phospholipids, spin-labeled, interaction with lipid A, 488
Piperacillin, microbiology and pharmacology of, clinical trials with, 13
Plague
immunization against in the military, 8
medieval, immunity in epidemiology of, 866 (historical article)
Plesiomonas shigelloides, enteritis due to, 633
Pneumococcal vaccine, alternatives to randomized clinical trials for, 589
Pneumonia
comparative study of cefonicid and cefamandole for treatment of, S847
in famous people, 810
due to *P. aeruginosa*, S657, S711
Poliomyelitis
control of, symposium on, S301–S600
control programs for
with IPV, S444–S466
with IPV and OPV, S467–S474
with OPV, S391–S443
by WHO, S475–S483
epidemiology of, eradication of, S308
frequency of, S371–S390
nonpolio enteroviruses mimicking, S379–S390
research on
immunology, S545–S568
molecular genetics, antigens, S484–S518, S528–S539
vaccines, S519–S527, S540
vaccines against
IPV, S335–S351, S444–S466
IPV and OPV, S467–S474
mechanisms and responses, S352–S370
OPV, S323–S334, S391–S443
world overview of, S302
Polyacrylamide gel electrophoresis, of *C. difficile* extracts, S229
Polymorphonuclear leukocytes, interaction with anaerobic bacteria, S40
Polysaccharides, capsular (*see* Capsular polysaccharides)
Pregnancy, associated depression of cell-mediated immunity in, 814
Primary health care, in developing countries
ascariasis, 364
Chagas' disease, 855
dengue, 251
diarrhea, acute, 840
leishmaniasis, 736
meningitis, acute bacterial, 374
opening address, International Congress for Infectious Diseases 265
trichuriasis, 364
Prophylaxis
antibiotic, for surgery, S880
comparison of cefonicid and cefazolin in prosthetic joint surgery, S901
comparison of cefonicid and cefoxitin for colorectal and small bowel surgery, S896
Prosthetic joint surgery, comparison of cefonicid and cefazolin for prophylaxis, S901
Pseudomembranous colitis
antibiotic-associated, S208
due to *C. difficile*, epidemiology of, S222
treatment of, S235
Pseudomonas aeruginosa
aquatic biofilms of, S608
cefsulodin, activity against
with aminoglycosides, S678
in burns, S744
in children, S751
compared to other agents, S667
in external otitis, S698
in lower respiratory tract infection, S711
in osteomyelitis, S728
predictors of response of, S759
in renal impairment, S689
in skin and soft tissue infection, S721
in urinary tract infection, S734
classic paper on, S775
clinical infection with, S603, S608, S627, S657
epidemiology of, S627
immunization against, S769
pneumonia, host defense mechanisms against, S657
prevention of and treatment for, summary, S769
resistance to antibiotics of, S643
virulence of, S617
Pseudomonas diminuta, lipid A of, 542
Pulmonary infection, due to anaerobic bacteria, S128
Pyopneumothorax, due to *C. perfringens*, 715
Renal dysfunction, in ceftazidime elimination, 732
Renal impairment or failure, kinetics of cefonicid in, S809
Renal insufficiency, modification of antibiotic dosage in, S803
Resistance, bacterial, selection for, S711
Respiratory tract infection (*see also* Pneumonia)
lower, due to *P. aeruginosa*, S705, S711
treatment with cefonicid, S835
Rheumatic fever, pathogenesis and autoimmune mechanisms of, 832
Rheumatoid arthritis, identifying infectious etiologies of, 200
Rhodopseudomonas species
R. gelatinosa, toxic lipid A of, 542
R. viridis, nontoxic lipid A of, 542
Rubella, immunization against in the military, 10
Salmonella minnesota
lipid A, structure of, 432
R595 lipopolysaccharide, analysis of lipid A from, 444
Salmonella, nontyphi, duration of excretion after infection with, carrier state with, 345
Salmonella typhimurium
effect of altered lipid A synthesis on synthesis of outer membrane proteins of, 455
stimulation of cells by lipid A precursor of, 535
Salmonellosis, due to nontyphi *Salmonella*, 345
Scotland, paralytic and nonpolio enteroviruses in, S385
Septic arthritis, in young infants, microbiology of, treatment of, 147
SIDS (*see* Sudden infant death syndrome)
Septicemia
in famous people, 805–807
with thermal injury, S744
Skin infections, due to *P. aeruginosa*, S721

Smadel, Joseph E., memorial lecture, involvement of in military medicine, 1
Small bowel surgery, comparison of cefonicid and cefoxitin prophylaxis, S896
Smallpox
  in famous people, 805–807
  immunization against in the military, 1
Smith, Theobald, letter to Edward Krumbhaar, 280 (classic paper)
Soft tissue infections
  due to *P. aeruginosa*, S721
  treatment with cefonicid, S835, S853
SSPE (*see* Subacute sclerosing panencephalitis)
Staphylococcus aureus
  abscesses due to, 122 (classic paper)
  endocarditis due to
    failure of treatment with cefonicid, S870
    treatment with cefonicid, S857
  susceptibility in vitro to β-lactam antibiotics, S829
Staphylococcus saprophyticus, urinary tract infection due to, 328
Statistical predictors of response, in therapy with cefsulodin, S759
Streptococci, group A, in rheumatic fever, 832
Streptococcus pneumoniae, vaccine, controversy about, 589
Subacute sclerosing panencephalitis, intensive exposure as risk factor for, 239
Sudden infant death syndrome, and *Clostridium* species, breast vs. bottle feeding, S193
Surgical prophylaxis
  for abdominal and gastrointestinal surgery, S276
  antibiotics in, S880
  comparison of cefonicid and cefazolin for prosthetic joint surgery, S901
  comparison of cefonicid and cefoxitin for biliary tract operations or hysterectomy, S887
  comparison of cefonicid and cefoxitin for colorectal and small bowel surgery, S896
Susceptibility testing, pH and protein effects, S829
Synergy, in microbial pathogenicity, S73
Syphilis, in famous people, 805–807
Systemic lupus erythematosus, identifying infectious etiologies of, 200
T cells, cytotoxic, in cytomegalovirus infection, 156
Tetanus
  epidemiology, clinical microbiology, treatment, prophylaxis, S202
  immunization against in the military, 8
  neonatal, in developed and developing countries, S202
  in thermal injury, S184
Thermal injury
  anaerobic infection following, S184
  host resistance, immunologic and hematologic alterations, 704
  infections due to *P. aeruginosa*, S744
Tobramycin, comparative trials of therapy for intraabdominal and female genital tract infections, S283
Tonsillitis, persistence of streptococci in, 601
Trichuriasis, epidemiology of, control of, 364
Trypanosoma cruzi
  and Chagas' disease, epidemiology and control, 855
  free radicals—mediated action of drugs and phagocytic cells on, 214
Tuberculosis
  in famous people, 805–807
  influence on Keats, 390
  Koch's postulates as related to AIDS, 270
Typhoid fever
  in famous people, 805–807
  immunization against in the military, 2
Typhus
  in famous people, 805–807
  immunization against in the military, 7
Urethritis, nongonococcal, epidemiology of, 669
Urinary tract infection
  in famous people, 809
  due to *P. aeruginosa*, S734
  due to *S. saprophyticus*, 328
  treatment with cefonicid, S835, S839, S844
USA, control of poliomyelitis in, S424
USSR, use of OPV in, S321
Utero-tubo-ovarian infection, rat model of, S96
Vaccines
  effectiveness of, against meningococcal disease, 640
  pneumococcal, alternatives to randomized clinical trials for, 589
  against poliomyelitis
    IPV, S335–S351, S444–S466
    mechanisms and responses, S352–S370
    OPV, S323–S334, S391–S443
    OPV and IPV, S467–S474
    research on, S484–S568
    WHO programs, S475–S483
Vancomycin, for treatment of pseudomembranous colitis, S235
Venereal urethritis, epidemiology of, 669
Viral interactions, possible, in AIDS, 726
Virulence factors, of anaerobic bacteria
  capsular polysaccharides of *B. fragilis*, S25
  enzymes of anaerobic gram-negative bacteria, S21
  Hageman factor, activation by *Bacteroides*, S30
  toxins of *C. difficile*, S11
Yellow fever, immunization against in the military, 7
Yersiniosis, serologic diagnosis of, 421, 880 (letters), 423 (reply)

Reviews of Infectious Diseases

An Official Publication of the Infectious Diseases Society of America

Edward H. Kass, Editor
Neil R. Blacklow, *Associate Editor*
John R. David, *Associate Editor*
Sherwood L. Gorbach, *Associate Editor*
Alice S. Huang, *Associate Editor*
Dennis L. Kasper, *Associate Editor*
Jerome O. Klein, *Associate Editor*

Mary M. Eichhorn Adams, *Assistant Editor*
Joan B. Daniels, *Managing Editor*
Nancy Kurz Voynow, *Managing Editor*
Maureen A. Hayes, *Manuscript Editor*
Julia M. Salas, *Manuscript Editor*
Steven Berman, *Editorial Assistant*
Sarah Acheson Stephens, *Staff Assistant*

EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.
Michael M. Frank, Bethesda, Md.
Lawrence R. Freedman, Los Angeles, Calif.
D. Carleton Gajdusek, Bethesda, Md.
King K. Holmes, Seattle, Wash.
Harold J. Jennings, Ottawa, Canada
Richard T. Johnson, Baltimore, Md.
Samuel L. Katz, Durham, N.C.
Thomas C. Merigan, Jr., Stanford, Calif.
Kenneth S. Warren, New York, N.Y.
Frank E. Young, Rochester, N.Y.

INTERNATIONAL BOARD OF DIRECTORS

Jacques F. Acar, Paris, France
Ralph van Furth, Leiden, The Netherlands
C. H. Huang, Beijing, China
Lars O. Kallings, Stockholm, Sweden
Jean Klastersky, Brussels, Belgium
P. Helena Mäkelä, Helsinki, Finland
Francis O'Grady, Nottingham, England
Theodore G. Sacks, Jerusalem, Israel
David A. J. Tyrrell, London, England
Yuichi Yamamura, Osaka, Japan

Volume 6

January–December 1984

All rights reserved
THE UNIVERSITY OF CHICAGO PRESS, CHICAGO
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON S.W. 1

© 1984 BY THE UNIVERSITY OF CHICAGO
PUBLISHED BIMONTHLY JANUARY–DECEMBER

Printed in USA

Reviews of Infectious Diseases

Volume 6 • Number 1 • January–February 1984

REVIEW ARTICLES

Abram S. Benenson	Immunization and Military Medicine	1
George L. Drusano, Stephen C. Schimpff, and William L. Hewitt	The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin	13
G. D. Hsiung, D. R. Mayo, H. L. Lucia, and M. L. Landry	Genital Herpes: Pathogenesis and Chemotherapy in the Guinea Pig Model	33
Charles A. Dinarello	Interleukin-1	51
J. B. Epstein, E. L. Truelove, and K. T. Izutzu	Oral Candidiasis: Pathogenesis and Host Defense	96

SERIAL FEATURES

J. W. M. van der Meer and P. J. van den Broek	Present Status of the Management of Patients with Defective Phagocyte Function	197

CLASSICS IN INFECTIOUS DISEASES

Alexander Ogston	"On Abscesses"	122

CORRESPONDENCE

Philip W. Smith	Objectivity Establishes Creditability	129
Calvin M. Kunin	The Relation Between Clinical Investigators and the Pharmaceutical Industry	129
William M. Nauseef	"Marriage of Heaven and Hell"	131
Charles M. Poser	Clinical Studies of Influenza Vaccines: Comment	132
John R. La Montagne	Reply	133
	ERRATUM (Bryan CS, Reynolds KL, Brenner ER, 5:629–638)	135
	NOTICES AND REPORT OF THE INTERNATIONAL CONGRESS FOR INFECTIOUS DISEASES	136
	REVIEWERS FOR VOLUME 5	139
	STATEMENT OF EDITORIAL POLICY AND INSTRUCTIONS TO AUTHORS	141

Volume 6 • Number 2 • March–April 1984

REVIEW ARTICLES

MICHAEL DAN — Septic Arthritis in Young Infants: Clinical and Microbiologic Correlations and Therapeutic Implications — 147

GERALD V. QUINNAN, JR., WILLIAM H. BURNS, NIGAR KIRMANI, ALAIN H. ROOK, JODY MANISCHEWITZ, LOZANNIE JACKSON, GEORGE W. SANTOS, AND REIN SARAL — HLA-Restricted Cytotoxic T Lymphocytes Are an Early Immune Response and Important Defense Mechanism in Cytomegalovirus Infections — 156

RAYMOND A. SMEGO, JR., AND HARRY A. GALLIS — The Clinical Spectrum of *Nocardia brasiliensis* Infection in the United States — 164

HENRY M. FEDER, JR. AND RICHARD A. GARIBALDI — The Significance of Nongonococcal, Nonmeningococcal Neisseria Isolates from Blood Cultures — 181

TOR HOFSTAD — Pathogenicity of Anaerobic Gram-Negative Rods: Possible Mechanisms — 189

CARL W. NORDEN AND LEWIS H. KULLER — Identifying Infectious Etiologies of Chronic Disease — 200

BENJAMIN A. LIPSKY, JOANN GATES, FRED C. TENOVER, AND JAMES J. PLORDE — Factors Affecting the Clinical Value of Microscopy for Acid-Fast Bacilli — 214

ROBERTO DOCAMPO AND SILVIA N. J. MORENO — Free Radical Metabolites in the Mode of Action of Chemotherapeutic Agents and Phagocytic Cells on *Trypanosoma cruzi* — 223

HYPOTHESIS

PETER AABY, JETTE BUKH, IDA MARIA LISSE, AND ARJON J. SMITS — Risk Factors in Subacute Sclerosing Panencephalitis: Age- and Sex-Dependent Host Reactions or Intensive Exposure? — 239

SERIAL FEATURES

SCOTT B. HALSTEAD — Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XI. Dengue — 251

INTERNATIONAL CONGRESS FOR INFECTIOUS DISEASES

HALFDAN MAHLER — Opening Address — 265

RICHARD M. KRAUSE — Koch's Postulates and the Search for the AIDS Agent — 270

CLASSICS IN INFECTIOUS DISEASES

THEOBALD SMITH — Letter to Edward Krumbhaar — 280

NOTICES — 282

Volume 6 • Supplement 1 • March–April 1984

	Participants	vii
Sydney M. Finegold	Introduction	S1
	ANAEROBIC BACTERIA	
	TAXONOMY	
Lillian V. Holdeman, Elizabeth P. Cato, and W. E. C. Moore	Taxonomy of Anaerobes: Present State of the Art	S3
	VIRULENCE FACTORS	
Yoshiko Banno, Toyoko Kobayashi, Hideki Kono, Kunitomo Watanabe, Kazue Ueno, and Yoshinori Nozawa	Biochemical Characterization and Biologic Actions of Two Toxins (D-1 and D-2) from *Clostridium difficile*	S11
H. Stephen Bjornson	Enzymes Associated with the Survival and Virulence of Gram-Negative Anaerobes	S21
Dennis L. Kasper, Alf A. Lindberg, Andrej Weintraub, Andrew B. Onderdonk, and Jörgen Lönngren	Capsular Polysaccharides and Lipopolysaccharides from Two Strains of *Bacteroides fragilis*	S25
H. Stephen Bjornson	Activation of Hageman Factor by Lipopolysaccharides of *Bacteroides fragilis*, *Bacteroides vulgatus*, and *Fusobacterium mortiferum*	S30
	HOST DEFENSES	
Ann B. Bjornson	Role of Complement in Host Resistance Against Members of the Bacteroidaceae	S34
Mark S. Klempner	Interactions of Polymorphonuclear Leukocytes with Anaerobic Bacteria	S40
	CLINICAL ANAEROBIC BACTERIOLOGY	
Hannele R. Jousimies-Somer and Sydney M. Finegold	Problems Encountered in Clinical Anaerobic Bacteriology	S45
Diane M. Citron	Specimen Collection and Transport, Anaerobic Culture Techniques, and Identification of Anaerobes	S51
William J. Martin, Peggy A. Wilhelm, and David Bruckner	Recovery of Anaerobic Bacteria from Vented Blood-Culture Bottles	S59
	ANAEROBES IN NORMAL FLORA AND THEIR ROLE IN PATHOGENIC PROCESSES OTHER THAN INFECTION	
Vera L. Sutter	Anaerobes as Normal Oral Flora	S62
John G. Bartlett and B. Frank Polk	Bacterial Flora of the Vagina: Quantitative Study	S67

Rial D. Rolfe	Interactions Among Microorganisms of the Indigenous Intestinal Flora and Their Influence on the Host	S73
Peter Corrodi	Jejunoileal Bypass: Change in the Flora of the Small Intestine and Its Clinical Impact	S80
Sherwood L. Gorbach	Estrogens, Breast Cancer, and Intestinal Flora: A Hypothesis	S85
	ANAEROBIC INFECTIONS	
	ANIMAL MODELS	
Andrew B. Onderdonk, Michael E. Shapiro, Robert W. Finberg, Dori F. Zaleznik, and Dennis L. Kasper	Use of a Model of Intraabdominal Sepsis for Studies of the Pathogenicity of *Bacteroides fragilis*	S91
Hunter A. Hammill, William E. Owens, Larry C. Ford, and Sydney M. Finegold	A Rat Model of Unilateral Utero-Tubo-Ovarian Abscess	S96
	SPECIFIC INFECTIONS	
Glenn E. Mathisen, Richard D. Meyer, W. Lance George, Diane M. Citron, and Sydney M. Finegold	Brain Abscess and Cerebritis	S101
Michael G. Newman	Anaerobic Oral and Dental Infection	S107
David F. Busch	Anaerobes in Infections of the Head and Neck and Ear, Nose, and Throat	S115
Patricia M. Murray and Sydney M. Finegold	Anaerobic Mediastinitis	S123
Atsushi Saito, Kohei Hara, Keizo Yamaguchi, and Toshiaki Usui	Pulmonary Infection Due to Anaerobes in a Hospital Survey	S128
Robert S. Bennion, Samuel E. Wilson, Arnold I. Serota, and Russell A. Williams	The Role of Gastrointestinal Microflora in the Pathogenesis of Complications of Mesenteric Ischemia	S132
David L. Dunn and Richard L. Simmons	The Role of Anaerobic Bacteria in Intraabdominal Infections	S139
Kaoru Shimada, Kyoko Urayama, Toshio Noro, and Takashi Inamatsu	Biliary Tract Infection with Anaerobes and the Presence of Free Bile Acids in Bile	S147
Jacobo Sabbaj	Anaerobes in Liver Abscess	S152
Margaret Lynn Yonekura, Maria Appleman, Roger Wallace, Marc Boucher, and Robert Nakamura	Predictive Value of Amniotic-Membrane Cultures for the Development of Postcesarean Endometritis	S157

Michael M. Nakata and Robert P. Lewis	Anaerobic Bacteria in Bone and Joint Infections	S165
Francisco L. Sapico, Joyce L. Witte, Hanna N. Canawati, John Z. Montgomerie, and Alice N. Bessman	The Infected Foot of the Diabetic Patient: Quantitative Microbiology and Analysis of Clinical Features	S171
Ellie J. C. Goldstein, Diane M. Citron, and Sydney M. Finegold	Role of Anaerobic Bacteria in Bite-Wound Infections	S177
Patricia M. Murray and Sydney M. Finegold	Anaerobes in Burn-Wound Infections	S184
Itzhak Brook	Anaerobic Infections in Childhood	S187
	INTOXICATIONS	
Stephen S. Arnon	Breast Feeding and Toxigenic Intestinal Infections: Missing Links in Crib Death?	S193
V. R. Dowell, Jr.	Botulism and Tetanus: Selected Epidemiologic and Microbiologic Aspects	S202
	ANTIMICROBIAL AGENT–INDUCED PSEUDOMEMBRANOUS COLITIS AND DIARRHEA	
W. Lance George	Antimicrobial Agent-Associated Colitis and Diarrhea: Historical Background and Clinical Aspects	S208
Joseph Silva, Robert Fekety, Christine Werk, Jack Ebright, Margaret Cudmore, Donald Batts, Charles Syrjamaki, and Jeff Lukens	Inciting and Etiologic Agents of Colitis	S214
Maury E. Mulligan	Epidemiology of *Clostridium difficile*-Induced Intestinal Disease	S222
Hannah Wexler, Maury E. Mulligan, and Sydney M. Finegold	Polyacrylamide Gel Electrophoresis Patterns Produced by *Clostridium difficile*	S229
John G. Bartlett	Treatment of Antibiotic-Associated Pseudomembranous Colitis	S235
	ANTIMICROBIAL AGENTS: SUSCEPTIBILITY TESTING, EFFECTS, PROPHYLAXIS, AND THERAPY	
Jon E. Rosenblatt	Antimicrobial Susceptibility Testing of Anaerobic Bacteria	S242
Ellen J. Baron and David A. Bruckner	Comparison of Susceptibilities of Anaerobic Bacteria Determined by Agar Dilution and a Microbroth Method	S249
Peter N. R. Heseltine, Maria D. Appleman, and John M. Leedom	Epidemiology and Susceptibility of Resistant *Bacteroides fragilis* Group Organisms to New β-Lactam Antibiotics	S254

Francis P. Tally, George J. Cucheral, Jr., and Michael H. Malamy	Mechanisms of Resistance and Resistance Transfer in Anaerobic Bacteria: Factors Influencing Antimicrobial Therapy	S260
C. E. Nord, A. Heimdahl, L. Kager, and A. S. Malmborg	The Impact of Different Antimicrobial Agents on the Normal Gastrointestinal Microflora of Humans	S270
Ronald Lee Nichols	Prophylaxis for Intraabdominal Surgery	S276
G. K. M. Harding, L. E. Nicolle, D. A. Haase, F. Y. Aoki, H. G. Stiver, R. J. Blanchard, and J. R. Kirkpatrick	Prospective, Randomized, Comparative Trials in the Therapy for Intraabdominal and Female Genital Tract Infections	S283
	A PERSPECTIVE	
A. T. Willis	Anaerobic Bacterial Diseases Now and Then: Where Do We Go From Here?	S293

Volume 6 • Number 3 • May-June 1984

	REVIEW ARTICLES	
Jonathan Freeman and John E. McGowan, Jr.	Methodologic Issues in Hospital Epidemiology. III. Investivestigating the Modifying Effects of Time and Severity of Underlying Illness on Estimates of Cost of Nosocomial Infection	285
Louis de Repentigny and Errol Reiss	Current Trends in Immunodiagnosis of Candidiasis and Aspergillosis	301
Thomas R. Navin and Dennis D. Juranek	Cryptosporidiosis: Clinical, Epidemiologic, and Parasitologic Review	313
Birgitta Hovelius and Per-Anders Mårdh	*Staphyloccus saprophyticus* as a Common Cause of Urinary Tract Infections	328
Stuart C. Gordon and Carl B. Lauter	Mumps Arthritis: A Review of the Literature	338
Dedra S. Buchwald and Martin J. Blaser	A Review of Human Salmonellosis: II. Duration of Excretion Following Infection with Nontyphi *Salmonella*	345
George L. Drusano, Patricia A. Ryan, Harold C. Standiford, Marcia R. Moody, and Stephen C. Schimpff	Integration of Selected Pharmacologic and Microbiologic Properties of Three New β-Lactam Antibiotics: A Hypothesis for Rational Comparison	357
	SERIAL FEATURES	
Fereydoun Arfaa	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XII. Ascariasis and Trichuriasis	364
B. M. Greenwood	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XIII. Acute Bacterial Meningitis	374
	HISTORICAL ARTICLES	
Hillas Smith	John Keats: Poet, Patient, Physician	390
	FROM THE INTERNATIONAL CONGRESS FOR INFECTIOUS DISEASES	
Sir Charles Stuart-Harris	Prospects for the Eradication of Infection Diseases	405

Hamao Umezawa	Studies on Low-Molecular-Weight Immunomodifiers Produced by Microorganisms: Results of Ten Years' Effort	412
	CORRESPONDENCE	
Emanuel Wolinsky	A Taxonomic Point	421
Kaisa Granfors and Auli Toivanen	ELISA and RIA for Serologic Diagnosis of Yersiniosis	421
Edward J. Bottone and Daniel J. Sheehan	Reply	423
	NOTICES	425

Volume 6 • Supplement 2 • May–June 1984

INTERNATIONAL SYMPOSIUM ON POLIOMYELITIS CONTROL

	Participants	vii
Dorothy M. Horstmann	Preface	S301
	SESSION I: CURRENT STATUS OF POLIOMYELITIS	
F. Assaad and K. Ljungars-Esteves	World Overview of Poliomyelitis: Regional Patterns and Trends	S302
Neal Nathanson	Epidemiologic Aspects of Poliomyelitis Eradication	S308
Natan Goldblum and Tiberio Swartz	The Israeli Experience in the Control of Poliomyelitis During a Quarter of a Century, 1957–1982	S313
Samuel Ofosu-Amaah	The Challenge of Poliomyelitis in Tropical Africa	S318
V. P. Grachev	Long-Term Use of Oral Poliovirus Vaccine from Sabin Strains in the Soviet Union	S321
	SESSION II: POLIOVIRUS VACCINES	
	Live Attenuated Vaccine	
Joseph L. Melnick	Live Attenuated Oral Poliovirus Vaccine	S323
Ronald J. Vallancourt	Current Poliovirus Vaccines	S328
Leslie Spence	Observations on the Use of Oral Poliovirus Vaccines in the Caribbean and Canada	S331
A. J. Beale	Live Attenuated Oral Poliovirus Vaccine: Problem Areas in Production	S334
	Formalin-Inactivated Vaccine	
A. L. van Wezel, G. van Steenis, P. van der Marel, and A. D. M. E. Osterhaus	Inactivated Poliovirus Vaccine: Current Production Methods and New Developments	S335
B. J. Montagnon, B. Fanget, and J. C. Vincent-Falquet	Industrial-Scale Production of Inactivated Poliovirus Vaccine Prepared by Culture of Vero Cells on Microcarrier	S341
A. v. Seefried, J. H. Chun, J. A. Grant, L. Letvenuk, and E. W. Pearson	Inactivated Poliovirus Vaccine and Test Development at Connaught Laboratories Ltd.	S345

H. Cohen and J. Nagel	Two Injections of Diphtheria-Tetanus-Pertussis–Polio Vaccine as the Backbone of a Simplified Immunization Schedule in Developing Countries	S350
	Modes of Action of and Response to Vaccines	
John P. Fox	Modes of Action of Poliovirus Vaccines and Relation to Resulting Immunity	S352
L. Å. Hanson, B. Carlsson, Fehmida Jalil, B. S. Lindblad, Shaukat Raza Khan, and A. L. van Wezel	Different Secretory IgA Antibody Responses After Immunization with Inactivated and Live Poliovirus Vaccines	S356
Pearay L. Ogra	Mucosal Immune Response to Poliovirus Vaccines in Childhood	S361
Tom D. Y. Chin	Immunity Induced by Inactivated Poliovirus Vaccine and Excretion of Virus	S369
	SESSION III: STRATEGIES FOR CONTROL	
	Assessment of Frequency of Paralytic Disease	
Roger H. Bernier	Some Observations on Poliomyelitis Lameness Surveys	S371
David L. Heymann	House-to-House and School Lameness Surveys in Cameroon: A Comparison of Two Methods for Estimating the Prevalence and Annual Incidence of Paralytic Poliomyelitis	S376
J. H. S. Gear	Nonpolio Causes of Polio-Like Paralytic Syndromes	S379
Norman R. Grist and Eleanor J. Bell	Paralytic Poliomyelitis and Nonpolio Enteroviruses: Studies in Scotland	S385
Joseph L. Melnick	Enterovirus Type 71 Infections: A Varied Clinical Pattern Sometimes Mimicking Paralytic Poliomyelitis	S387
	Control Programs	
	Use of Live Attenuated Vaccine	
Albert B. Sabin	Strategies for Elimination of Poliomyelitis in Different Parts of the World with Use of Oral Poliovirus Vaccine	S391
Jorge Fernández de Castro	Mass Vaccination Against Poliomyelitis in Mexico	S397
João Baptista Risi, Jr.	The Control of Poliomyelitis in Brazil	S400
Andrew L. Creese	Cost Effectiveness of Alternative Strategies for Poliomyelitis Immunization in Brazil	S404
Rodolfo Rodriguez Cruz	Cuba: Mass Polio Vaccination Program, 1962–1982	S408
I. Dömök	Experiences Associated with the Use of Live Poliovirus Vaccine in Hungary, 1959–1982	S413
Francis E. André	Control of Poliomyelitis by Vaccination in Belgium	S419
Lawrence B. Schonberger, Jonathan Kaplan, Robert Kim-Farley, Melinda Moore, Donald L. Eddins, and Milford Hatch	Control of Paralytic Poliomyelitis in the United States	S424
Hiroto Shimojo	Poliomyelitis Control in Japan	S427

Dong De-xiang	Immunization with Oral Poliovirus Vaccine in China	S431
Pang Qi-fang	Some Problems of Administering Oral Poliovirus Vaccine	S432
Stanley O. Foster, Georges Kesseng-Maben, Hatib N'jie, and Emmou Coffi	Control of Poliomyelitis in Africa	S433
T. Jacob John	Poliomyelitis in India: Prospects and Problems of Control	S438
Emilia M. León de Coto	Evolution of the Poliomyelitis Vaccination Program in Costa Rica	S442
	Use of Inactivated Vaccine	
Jonas Salk	One-Dose Immunization Against Paralytic Poliomyelitis Using a Noninfectious Vaccine	S444
Henk Bijkerk	Surveillance and Control of Poliomyelitis in The Netherlands	S451
Kaisa Lapinleimu	Elimination of Poliomyelitis in Finland	S457
Nils Oker-Blom, Kari Penttinen, and Pertti Weckström	Inactivated Poliovirus Vaccine in Finland	S461
P. Stoeckel, M. Schlumberger, G. Parent, B. Maire, A. van Wezel, G. van Steenis, A. Evans, and D. Salk	Use of Killed Poliovirus Vaccine in a Routine Immunization Program in West Africa	S463
	Use of Both Attenuated and Inactivated Vaccines	
E. E. Lasch, Y. Abed, K. Abdulla, A. G. El Tibbi, O. Marcus, M. El Massri, R. Handscher, C. B. Gerichter, and J. L. Melnick	Successful Results of a Program Combining Live and Inactivated Poliovirus Vaccines to Control Poliomyelitis in Gaza	S467
Herdis von Magnus and Inger Petersen	Vaccination with Inactivated Poliovirus Vaccine and Oral Poliovirus Vaccine in Denmark	S471
	World Health Organization Programs	
Ralph H. Henderson	The Expanded Programme on Immunization of the World Health Organization	S475
J. F. Martin	Consequences of the Introduction of the New Inactivated Poliovirus Vaccine into the Expanded Programme on Immunization	S480
Holger Lundbeck	Strategies for Control: A Discussion	S483
	SESSION IV: CURRENT RESEARCH	
David Baltimore	Molecular Genetics of Poliovirus	S484
J. W. Almond, A. J. Cann, P. D. Minor, P. Reeve, G. C. Schild, R. Hauptmann, and G. Stanway	Nucleotide Sequence from Neurovirulent and Attenuated Strains of Type 3 Poliovirus	S487
Akio Nomoto, Haruka Toyoda, Yutaka Kataoka, Michinori Kohara, Toshiyuki Suganuma, Toshiko Omata, Nobumasa Imura	Approaches to the Development of New Poliovirus Vaccines Based on Molecular Genetics	S494
Olen M. Kew and Baldev K. Nottay	Molecular Epidemiology of Polioviruses	S499
Eckard Wimmer, Emilio A. Emini, and Bradford A. Jameson	Peptide Priming of a Poliovirus Neutralizing Antibody Response	S505

M. Ferguson, P. D. Minor, D. I. Magrath, M. Spitz, and G. C. Schild	Antigenic Characterization of Poliovirus Type 3 Using Monoclonal Antibodies	S510
Vincent R. Racaniello	Studying Poliovirus with Infectious Cloned cDNA	S514
P. D. Minor, D. M. A. Evans, G. C. Schild, M. Ferguson, and J. W. Almond	Identification of an Antigenic Site in the Neutralization of Type 3 Poliovirus	S516
Bennett L. Elisberg	Standardization of Safety and Potency Tests of Vaccines Against Poliomyelitis	S519
Frank T. Perkins	The Standardization of Vaccines: A Discussion	S523
Max A. Chernesky	Current Advances in Viral Diagnostic Technology Applicable to Polio Vaccination and Diagnosis	S525
John Furesz, Ralph E. Armstrong, Guillermo Contreras, and Brenda Wachmann	Genetic Characterization of Poliovirus Isolates in Canada, 1962–1981	S528
R. Crainic, B. Blondel, and F. Horaud	Antigenic Variation of Poliovirus Studied by Means of Monoclonal Antibodies	S535
Paul Albrecht, G. van Steenis, A. L. van Wezel, and Jonas Salk	Standardization of Poliovirus Neutralizing Antibody Tests	S540
B. Grenier, B. Hamza, G. Biron, C. Xueref, F. Viarme, and M. Roumiantzeff	Seroimmunity Following Vaccination in Infants by an Inactivated Poliovirus Vaccine Prepared on Vero Cells	S545
Margareta Böttiger	Long-Term Immunity Following Vaccination with Killed Poliovirus Vaccine in Sweden, a Country with No Circulating Poliovirus	S548
A. M. McBean, M. L. Thoms, R. H. Johnson, B. R. Gadless, B. MacDonald, L. Nerhood, P. Cummins, J. Hughes, J. Kinnear, C. Watts, M. Kraft, P. Albrecht, E. J. Boone, M. Moore, J. A. Frank, Jr., and R. Bernier	A Comparison of the Serologic Responses to Oral and Injectable Trivalent Poliovirus Vaccines	S552
T. A. Swartz, E. Ben-Porath, H. Kanaaneh, L. Leitner, and N. Goldblum	Comparison of Inactivated Poliovirus Vaccine and Oral Poliovirus Vaccine Programs in Israel	S556
Marinos C. Dalakas, John L. Sever, David L. Madden, Nicholas M. Papadopoulos, Isabel C. Shekarchi, Paul Albrecht, and Aurella Krezlewicz	Late Postpoliomyelitis Muscular Atrophy: Clinical, Virologic, and Immunologic Studies	S562
Richard T. Johnson	Late Progression of Poliomyelitis Paralysis: Discussion of Pathogenesis	S568
	SESSION V: PROSPECTS FOR WORLDWIDE CONTROL	
Alfred S. Evans	Criteria for Assessing Accomplishment of Poliomyelitis Control	S571
Michael B. Gregg	Paralytic Poliomyelitis Can Be Eliminated	S577
James Chin	Can Paralytic Poliomyelitis be Eliminated?	S581

David Robinson	Political, Administrative, and Economic Resources for the Control of Poliomyelitis	S586
Andrew L. Creese	Priorities in Health Care: A Discussion	S589
N. A. Ward	Practicalities of a Global Poliomyelitis Control Program	S591
William S. Jordan, Jr.	Prospects for Worldwide Control of Paralytic Poliomyelitis: A Discussion	S594
Frederick C. Robbins	Summary and Recommendations	S596
	* * *	
	NOTICES	S601

Volume 6 • Number 4 • July-August 1984

MOLECULAR CONCEPTS OF LIPID A

	Participants	v
C. R. Alving and D. C. Morrison	Foreword	427
	SYMPOSIUM I. STRUCTURAL ASPECTS OF LIPID A	
O. Lüderitz, K. Tanamoto, C. Galanos, G. R. McKenzie, H. Brade, U. Zähringer, E. Th. Rietschel, S. Kusumoto, and T. Shiba	Lipopolysaccharides: Structural Principles and Biologic Activities	428
E. Th. Rietschel, H.-W. Wollenweber, R. Russa, H. Brade, and U. Zähringer	Concepts of the Chemical Structure of Lipid A	432
K. Takayama, N. Qureshi, E. Ribi, and J. L. Cantrell	Separation and Characterization of Toxic and Nontoxic Forms of Lipid A	439
I. Mattsby-Baltzer, P. Gemski, and C. R. Alving	Heterogeneity of Lipid A	444
M. Batley, P. A. McNicholas, N. H. Packer, and J. W. Redmond	Analysis of Lipid A from *Salmonella minnesota* R595 Lipopolysaccharide by Chemical Methods and Nuclear Magnetic Resonance	449
C. R. Verret	Lipases Specifically Degrading Lipopolysaccharide: Fatty Acyl Amidases from *Dictyostelium discoideum*	452
	SYMPOSIUM II. SYNTHESIS OF LIPID A	
P. D. Rick, B. A. Neumeyer, and D. A. Young	Effect of Altered Lipid A Synthesis on the Synthesis of Major Proteins of the *Salmonella typhimurium* Outer Membrane	455
C. R. H. Raetz	The Enzymatic Synthesis of Lipid A: Molecular Structure and Biologic Function of Monosaccharide Precursors	463
L. Anderson and M. A. Nashed	A Convergent Approach to the Synthesis of Lipid A	472
T. Shiba, S. Kusumoto, M. Inage, M. Imoto, H. Chaki, and T. Shimamoto	Recent Developments in the Organic Synthesis of Lipid A in Relation to Biologic Activities	478
M. A. Freudenberg, B. Kleine, and C. Galanos	The Fate of Lipopolysaccharide in Rats: Evidence for Chemical Alteration in the Molecule	483

SYMPOSIUM III. INTERACTION OF LIPID A WITH MEMBRANES

Y. Takeuchi and H. Nikaido	Physical Interaction Between Lipid A and Phospholipids: A Study with Spin-Labeled Phospholipids	488
C. R. Alving and E. C. Richardson	Mitogenic Activities of Lipid A and Liposome-Associated Lipid A: Effects of Epitope Density	493
C. Carr, Jr., and D. C. Morrison	A Two-Step Mechanism for the Interaction of Re Lipopolysaccharide with Erythrocyte Membranes	497
D. M. Jacobs	Structural Features of Binding of Lipopolysaccharides to Murine Lymphocytes	501
M. Kern	Selective Binding of Lipid A to Responder and Nonresponder B Lymphocyte Subpopulations	506
S. A. Goodman, S. W. Vukajlovich, P. Munkenbeck, and D. C. Morrison	Selective Interaction Between Lymphocytes and Lipid A Subunits in Lipopolysaccharide Macromolecular Aggregates	511

SYMPOSIUM IV. INTERACTION OF LIPID A WITH LYMPHOCYTES AND MACROPHAGES

S. E. Mergenhagen and D. H. Pluznik	Defective Responses to Lipid A in C3H/HeJ Mice: Approaches to an Understanding of Lipid A–Cell Interaction	519
S. Forsgren, B. Kleine, G. Pobor, C. Martinez-A., L. Forni, and A. Coutinho	The Membrane Receptor Complex Regulating Induction and Clonal Expansion of Normal Murine B Lymphocytes	524
S. W. Vukajlovich and D. C. Morrison	Lipid A–Dependent Lymphocyte Proliferation in "Endotoxin-Nonresponder" Mice	528
E. C. Richardson and C. R. Alving	Mitogenic Response of Lymphocytes from C3H/HeJ Mice in the Presence of Lipid A and Lipid A Fractions	532
S. N. Vogel, G. S. Madonna, L. M. Wahl, and P. D. Rick	Stimulation of Spleen Cells and Macrophages of C3H/HeJ Mice by a Lipid A Precursor Derived from *Salmonella typhimurium*	535
H. Mayer, P. V. Salimath, O. Holst, and J. Weckesser	Unusual Lipid A Types in Phototropic Bacteria and Related Species	542

SYMPOSIUM V. LIPID A IMMUNOLOGY AND HOST PROTECTION

C. Galanos, M. A. Freudenberg, F. Jay, D. Nerkar, K. Veleva, H. Brade, and W. Strittmatter	Immunogenic Properties of Lipid A	546
I. Mattsby-Baltzer and C. R. Alving	Antibodies to Lipid A: Occurrence in Humans	553
S. C. Kinsky	Effects of Lipid A on the Immunologic Properties of Liposomal Model Membranes	558
N. F. Pierce, J. B. Sacci, Jr., C. R. Alving, and E. C. Richardson	Enhancement by Lipid A of Mucosal Immunogenicity of Liposome-Associated Cholera Toxin	563
E. Ribi, J. L. Cantrell, K. Takayama, N. Qureshi, J. Peterson, and H. O. Ribi	Lipid A and Immunotherapy	567
	ABSTRACTS OF THE SYMPOSIUM	573

CLASSICS IN INFECTIOUS DISEASES

S. E. BRANHAM — Toxic Products of Bacterium enteritidis and of Related Micro-Organisms — 579

NOTICES — 587

Volume 6 • Number 5 • September–October 1984

REVIEW ARTICLES

JOHN D. CLEMENS AND EUGENE D. SHAPIRO — Resolving the Pneumococcal Vaccine Controversy: Are There Alternatives to Randomized Clinical Trials? — 589

ITZHAK BROOK — The Role of β-Lactamase-Producing Bacteria in the Persistence of Streptococcal Tonsillar Infection — 601

M. KOSKINIEMI, A. VAHERI, AND E. TASKINEN — Cerebrospinal Fluid Alterations in Herpes Simplex Virus Encephalitis — 608

A. K. BHATTACHARJEE, J. E. BENNETT, AND C. P. J. GLAUDEMANS — Capsular Polysaccharides of *Cryptococcus neoformans* — 619

MARTIN J. BLASER, ARTHUR L. REINGOLD, ROBERT N. ALSEVER, AND ALLEN HIGHTOWER — Primary Meningococcal Pericarditis: A Disease of Adults Associated with Serogroup C *Neisseria meningitidis* — 625

SCOTT D. HOLMBERG AND J. J. FARMER III — *Aeromonas hydrophila* and *Plesiomonas shigelloides* as Causes of Intestinal Infections — 633

GEORGE W. COUNTS, DAVID F. GREGORY, JEAN G. SPEARMAN, BARRETT A. LEE, GREGORY A. FELICE, KING K. HOLMES, J. MCLEOD GRIFFISS, AND THE PACIFIC NORTHWEST MENINGOCOCCAL STUDY GROUP — Group A Meningococcal Disease in the U.S. Pacific Northwest: Epidemiology, Clinical Features, and Effect of a Vaccination Control Program — 640

PHILIP A. MACKOWIAK — Microbial Latency — 649

J. ALLEN MCCUTCHAN — Epidemiology of Venereal Urethritis: Comparison of Gonorrhea and Nongonococcal Urethritis — 669

LOUISE S. TASHJIAN, JON S. ABRAMSON, AND JAMES E. PEACOCK, JR. — Focal Hepatic Candidiasis: A Distinct Clinical Variant of Candidiasis in Immunocompromised Patients — 689

ANN B. BJORNSON AND H. STEPHEN BJORNSON — Theoretical Interrelationships Among Immunologic and Hematologic Sequelae of Thermal Injury — 704

MARTIN J. RAFF, JUDITH D. JOHNSON, DEEPAK NAGAR, FRED Z. FERRIS, AND MARY L. MCCORMICK — Spontaneous Clostridial Empyema and Pyopneumothorax — 715

EDITORIALS

ARNOLD S. MONTO — Epidemiologic Designs for the Study of Acquired Immunodeficiency Disease: Options and Obstacles — 720

MARTIN S. HIRSCH, ROBERT T. SCHOOLEY, DAVID D. HO, AND JOAN C. KAPLAN — Possible Viral Interactions in the Acquired Immunodeficiency Syndrome (AIDS) — 726

HYPOTHESES

PREM K. NARANG AND JAMES R. HUNTER — Is Renal Function the Only Determinant in the Elimination of Ceftazidime? — 732

SERIAL FEATURES

PHILIP D. MARSDEN — Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XIV. Leishmaniasis — 736

FROM THE INTERNATIONAL CONGRESS FOR INFECTIOUS DISEASES

J. G. SINKOVICS, F. GYORKEY, J. L. MELNICK, AND P. GYORKEY — Acquired Immune Deficiency Syndrome (AIDS): Speculations About Its Etiology and Comparative Immunology — 745

CLASSICS IN INFECTIOUS DISEASES

ELIE METCHNIKOFF — Concerning the Relationship Between Phagocytes and Anthrax Bacilli — 761

CORRESPONDENCE

CHARLES M. BUMP — Acid-Fast Smear for *Mycobacterium tuberculosis* — 771

ERRATUM (STD Treatment Guidelines 1982:4;S740) — 771

NOTICES — 772

Volume 6 • Supplement 3 • September–October 1984

PSEUDOMONAS AERUGINOSA—BIOLOGY, IMMUNOLOGY, AND THERAPY: A CEFSULODIN SYMPOSIUM

Participants — v

INTRODUCTION

LOWELL S. YOUNG — The Clinical Challenge of Infections Due to *Pseudomonas aeruginosa* — S603

BIOLOGY AND IMMUNOLOGY OF INFECTIONS DUE TO *PSEUDOMONAS AERUGINOSA*

J. W. COSTERTON — The Etiology and Persistence of Cryptic Bacterial Infections: A Hypothesis — S608

MATTHEW POLLACK — The Virulence of *Pseudomonas aeruginosa* — S617

ALLAN J. MORRISON, JR., AND RICHARD P. WENZEL — Epidemiology of Infections Due to *Pseudomonas aeruginosa* — S627

L. D. SABATH — Biochemical and Physiologic Basis for Susceptibility and Resistance of *Pseudomonas aeruginosa* to Antimicrobial Agents — S643

JAMES E. PENNINGTON, MICHAEL G. EHRIE, AND WILLIAM F. HICKEY — Host Defense Mechanisms Against Pneumonia Due to *Pseudomonas aeruginosa* — S657

ANTIMICROBIAL SPECTRUM AND CLINICAL TRIALS WITH CEFSULODIN

HAROLD C. NEU AND BRIAN E. SCULLY — Activity of Cefsulodin and Other Agents Against *Pseudomonas aeruginosa* — S667

STEPHEN A. LERNER, EDWARD J. DUDEK, WILLIAM E. BOISVERT, AND KURT D. BERNDT — Effect of Highly Potent Antipseudomonal β-Lactam Agents Alone and in Combination with Aminoglycosides Against *Pseudomonas aeruginosa* — S678

THOMAS P. GIBSON, G. RICHARD GRANNEMAN, JOHN E. KALLAL, AND LAWRENCE T. SENNELLO — Kinetics of Cefsulodin in Patients with Renal Impairment — S689

MERYL H. MENDELSON, BURT R. MEYERS, SHALOM Z. HIRSCHMAN, ELYSE R. SHAPIRO, AND SIMON C. PARISIER — Treatment of Invasive External Otitis with Cefsulodin — S698

DANIEL B. CAPLAN AND CONNIE N. BUCHANAN — Treatment of Lower Respiratory Tract Infections Due to *Pseudomonas aeruginosa* in Patients with Cystic Fibrosis — S705

LARRY NICHOLS, SIGURDUR GUDMUNDSSON, AND DENNIS G. MAKI — Experience with Cefsulodin Therapy for Lower Respiratory Tract Infections Caused by *Pseudomonas aeruginosa* in Adults Without Cystic Fibrosis or Granulocytopenia — S711

WILLIAM J. MOGABGAB — Treatment of Skin and Soft-Tissue Infections with Cefsulodin — S721

JOHN C. POTTAGE, JR., PETER H. KARAKUSIS, AND GORDON M. TRENHOLME — Cefsulodin Therapy for Osteomyelitis Due to *Pseudomonas aeruginosa* — S728

HARVEY A. ELDER AND IRA ROY — Treatment of Urinary Tract Infections Due to *Pseudomonas aeruginosa* with Cefsulodin — S734

DAVID M. HEIMBACH — Cefsulodin Therapy for Infections Due to *Pseudomonas aeruginosa* in Patients with Burns — S744

T. NISHIMURA AND R. FUJII — Clinical and Pharmacokinetic Study of Parenteral Administration of Cefsulodin in Pediatric Patients in Japan — S751

RICHARD PLATT — Predictors of Response to Therapy for Infections Caused by *Pseudomonas aeruginosa* — S759

SUMMARY

LOWELL S. YOUNG, RICHARD P. WENZEL, LEON D. SABATH, MATTHEW POLLACK, JAMES E. PENNINGTON, AND RICHARD PLATT — The Outlook for Prevention and Treatment of Infections Due to *Pseudomonas aeruginosa* — S769

CLASSICS IN INFECTIOUS DISEASES

CARLE GESSARD — On the Blue and Green Coloration that Appears on Bandages — S775

Volume 6 • Number 6 • November–December 1984

REVIEW ARTICLES

M. L. TAYLOR, S. DIAZ, P. A. GONZALEZ, A. C. SOSA, AND C. TORIELLO — Relationship Between Pathogenesis and Immune Regulation Mechanisms in Histoplasmosis: A Hypothetical Approach — 775

Marilyn M. P. Tsao and David Katz	Central Venous Catheter–Induced Endocarditis: Human Correlate of the Animal Experimental Model of Endocarditis	783
Raymond A. Smego Jr., John R. Perfect, and David T. Durack	Combined Therapy with Amphotericin B and 5-Fluorocytosine for Candida Meningitis	791
Stephen A. Berger and Stephen C. Edberg	Infectious Diseases in Persons of Leadership	802
Eugene D. Weinberg	Pregnancy-Associated Depression of Cell-Mediated Immunity	814
David Senitzer and Earl H. Freimer	Autoimmune Mechanisms in the Pathogenesis of Rheumatic Fever	832
	SERIAL FEATURES	
Jon Eliot Rohde	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XV. Acute Diarrhea	840
Philip Davis Marsden	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XVI. Chagas' Disease	855
	HISTORICAL ARTICLES	
Stephen R. Ell	Immunity as a Factor in the Epidemiology of Medieval Plague	866
	CORRESPONDENCE	
Stefan Lange and Peter Larsson	What Do Serum Antibodies to *Yersinia enterocolitica* Indicate?	880
	NOTICES	882
	INDEXES TO VOLUME 6	
	Author Index	883
	Subject Index	887
	Contents for Volume 6	iii

Volume 6 • Supplement 4 • November–December 1984

	CLINICAL AND ECONOMIC IMPACT OF CEFONICID	
	Participants	v
John E. Conte, Jr.	Clinical and Economic Impact of Cefonicid: Overview and Summary of the Symposium	S777
	SESSION I: OVERVIEW OF IN VITRO AND CLINICAL EXPERIENCE	
Paul Actor	In Vitro Experience with Cefonicid	S783
Leonard S. Jacob and Porter Layne	Cefonicid: An Overview of Clinical Studies in the United States	S791
	SESSION II: PHARMACOKINETIC CHARACTERISTICS	
Ralph E. Cutler	An Overview of Pharmacokinetics	S803
Steven L. Barriere, John G. Gambertoglio, Donald P. Alexander, Robert J. Stagg, and John E. Conte, Jr.	Pharmacokinetic Disposition of Cefonicid in Patients with Renal Failure and Receiving Hemodialysis	S809

Sister Mary Ann Lou, Y. H. Wu, L. S. Jacob, and D. H. Pitkin	Penetration of Cefonicid into Human Breast Milk and Various Body Fluids and Tissues	S816
Charles H. Nightingale, Richard Quintiliani, Michael N. Dudley, Patricia Gough, Mark Hickingbotham, Nancy Schuddekopf Jordan, Deborah Rose, and Michael Toscani	Tissue Penetration and Half-Life of Cefonicid	S821
Richard Platt and Bernard Rosner	Effect of Hydrogen Ion and Protein Concentrations on the Activity of β-Lactam Antibiotics	S829
	SESSION III: EFFICACY IN URINARY TRACT, RESPIRATORY TRACT, AND SOFT-TISSUE INFECTIONS	
Donald Kaye	An Overview: Evaluation of Cefonicid in Infections of the Urinary Tract, Lower Respiratory Tract, and Skin and Soft Tissue	S835
C. E. Cox and L. S. Jacob	Treatment of Urinary Tract Infections in Hospitalized Patients: A Double-Blind Comparison of Cefonicid and Cefamandole	S839
S. I. Morgan, R. E. Pontzer, L. M. Cortez, S. L. Guice, W. Brannan, R. E. Krieger, W. McNamee, J. A. Boscia, M. E. Levison, and D. Kaye	Single-Dose Regimen of Cefonicid for the Treatment of Uncomplicated Infections of the Lower Urinary Tract	S844
Ronald W. Geckler, Gregory D. McCormack, and Jay S. Goodman	Comparison of Cefonicid and Cefamandole for the Treatment of Community-Acquired Infections of the Lower Respiratory Tract	S847
Gary Slutkin, Joseph Marzouk, Lawrence Dall, and John Mills	Comparison of Cefonicid and Cefazolin for Treatment of Soft-Tissue Infections	S853
	SESSION IV: SPECIAL STUDIES	
Jon T. Mader and James A. Reinarz	Treatment of Bacterial Osteomyelitis and *Staphylococcus aureus* Endocarditis and Single-Dose Therapy for Uncomplicated *Neisseria gonorrhoeae* Infections: An Overview	S857
Mark J. Kunkel and Paul B. Iannini	Cefonicid in a Once-Daily Regimen for Treatment of Osteomyelitis in an Ambulatory Setting	S865
Henry F. Chambers, John Mills, Thomas A. Drake, and Merle A. Sande	Failure of a Once-Daily Regimen of Cefonicid for Treatment of Endocarditis Due to *Staphylococcus aureus*	S870
W. Christopher Duncan and M. E. McBride	Single-Dose Treatment of Uncomplicated Gonorrhea: A Comparison of Cefonicid and Penicillin	S875
	SESSION V: SURGICAL PROPHYLAXIS	
Richard Platt	Antibiotic Prophylaxis in Surgery	S880
Dennis G. Maki, Jan L. Lammers, and David R. Aughey	Comparative Studies of Multiple-Dose Cefoxitin vs. Single-Dose Cefonicid for Surgical Prophylaxis in Patients Undergoing Biliary Tract Operations or Hysterectomy	S887
Timothy C. Fabian, Eugene C. Mangiante, and Sandra J. Boldreghini	Prophylactic Antibiotics for Elective Colorectal Surgery or Operation for Obstruction of the Small Bowel: A Comparison of Cefonicid and Cefoxitin	S896

KENNETH J. DEBENEDICTIS, NOEL M. ROWAN, AND BENITA L. BOYER	A Double-Blind Study Comparing Cefonicid with Cefazolin as Prophylaxis in Patients Undergoing Total Hip or Knee Replacement	S901
	SESSION VI: ECONOMIC CONSIDERATIONS	
JOHN M. EISENBERG	New Drugs and Clinical Economics: Analysis of Cost Effectiveness in the Assessment of Pharmaceutical Innovations	S905
JOHN M. EISENBERG, HARRIS KOFFER, AND STEVEN A. FINKLER	Economic Analysis of a New Drug: Potential Savings in Hospital Operating Costs from the Use of a Once-Daily Regimen of a Parenteral Cephalosporin	S909
DAVID J. TANNER	Cost Containment of Reconstituted Parenteral Antibiotics: Personnel and Supply Costs Associated with Preparation, Dispensing, and Administration	S924